Thermo Fisher Scientific, the global leader in serving science, and Arsenal Biosciences, Inc. , a cell therapy clinical development company, to develop novel chimeric antigen receptor (CAR)-T cell therapies ) for solid tumors, announced the update of their strategic collaboration to further advance the manufacturing process for novel cancer treatments. This research and process development oriented collaboration will enable ArsenalBio to develop a robust manufacturing process for its next-generation programmable autologous T cells for cancer treatment.
ArsenalBio recently enabled the transition of its lead product candidate into the clinical manufacturing process of its autologous ICT therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multifunctional CAR T-cell therapies is enabled by Fisher’s portfolio of Cell Therapy Systems (CTS) products, including the Gibco CTS Xenon Electroporation System and the Gibco CTS Rotea Counterflow Centrifugation System.
Also Read: WIPO Publishes Aquavit’s Methods for Delivering Bioactive Compositions and Formulations to the Skin
“Our programmable cell therapy technology has the potential to benefit patients with aggressive and complex cancers who currently have few treatment options,” said Ken Drazan, MD, co-founder and CEO of ArsenalBio. “To deliver on the promise of this technology to patients, we need to transition to clinical development quickly and at scale. Our relationship with Thermo Fisher allows us to combine their real-world solutions and in-house knowledge with the innovative approach of our team’s clinical research and process development expertise to manufacture ArsenalBio’s products and explore future therapeutic innovations.”
Thermo Fisher began its collaboration with ArsenalBio in 2020 to help ArsenalBio solve the challenges associated with cell therapy manufacturing by collaborating to support the development of a clinical-scale gene editing process. In addition, ArsenalBio will have early access to Thermo Fisher’s latest instrumentation and reagents.
SOURCE: Businesswire